425: NLS Pharmaceutics CEO Details Strategic Milestones and Merger Progress with Kadimastem

NLS Pharmaceutics' CEO provides a comprehensive update on recent financing, positive clinical developments, and the anticipated merger with Kadimastem, targeting early Q3 2025 completion.

Summary

• NLS Pharmaceutics has completed major financing events, raising aggregate gross proceeds of $2.5 million in Q1 2025 through two equity financing transactions.
• Shares were priced at $3.10 (48% premium) and $1.65 (10% premium) to market price at the time of transactions.
• The company secured a $25 million equity facility commitment to support the merger with Kadimastem Ltd. and advance clinical programs.
• Over $6 million has been raised in aggregate to support the pending merger and the combined company's post-merger clinical trials.
• All outstanding company liabilities have been converted into equity, resulting in a debt-free balance sheet and extended cash runway.
• Positive preclinical data for AEX-2 (dual orexin receptor agonist platform) for CNS disorders was announced in February 2025.
• Kadimastem and iTolerance successfully completed a Pre-IND Meeting with the FDA in February 2025 for their Type 1 Diabetes Treatment.
• Positive results from Study KO-943 in April 2025 showed Mazindol ER significantly reduced fentanyl-induced reward behaviors in animal models.
• The merger with Kadimastem was overwhelmingly approved by Kadimastem's shareholders in January 2025, following board approvals from both companies.
• Amendments to the Registration Statements on Form F-4 have been filed, paving the way for the final NLS shareholder vote.
• The merger is targeted for completion in early Q3 2025, subject to regulatory requirements.
• The combined entity will be named NewcelX, intending to be a Nasdaq-listed clinical-stage biotech.
• NewcelX's robust pipeline will include AstroRx (ALS, Phase IIa), IsletRx (diabetes), and CNS disorders via the DOXA platform (AEX-2/AEX-41).
• NLS shareholders are expected to benefit from legacy assets like Mazindol ER through contingent value rights.

Sentiment

Score: 8

Explanation: The document conveys a highly optimistic and positive outlook, emphasizing successful financing, promising clinical data, and smooth progress towards a transformative merger. The language consistently highlights achievements, strategic positioning, and future value creation, with risks only mentioned in the standard safe harbor statement.

Positives

• Successful completion of two equity financing transactions in Q1 2025, raising $2.5 million at premiums of 48% and 10% to market share price.
• Secured a significant $25 million equity facility commitment, enhancing the combined company's balance sheet and providing flexibility for future pipeline development.
• Raised over $6 million in aggregate to support the merger and post-merger clinical trials.
• Conversion of all outstanding liabilities into equity, resulting in a strong, debt-free balance sheet and extended cash runway.
• Positive preclinical data for AEX-2, validating the dual orexin receptor agonist platform for CNS disorders.
• Successful completion of a Pre-IND Meeting with the FDA for Kadimastem's Type 1 Diabetes Treatment, a significant asset for the merged company.
• Positive results from Study KO-943 demonstrating Mazindol ER's potential to reduce fentanyl-induced reward behaviors, providing proof-points for safety and therapeutic potential.
• Overwhelming shareholder approval from Kadimastem for the merger, indicating strong support for the strategic combination.
• The merger is progressing towards an anticipated early Q3 2025 completion, creating a diversified clinical-stage biotech with a robust pipeline.
• The combined entity, NewcelX, will have a fortified capital structure and a unified board, strategically positioned for value creation.

Risks

• Risks related to the companies' ability to complete the Merger on the proposed terms and schedule, including satisfaction of closing conditions and obtaining shareholder approvals.
• Potential for unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger.
• Changes in technology and market requirements could impact the combined company.
• Either company may encounter delays or obstacles in launching and/or successfully completing their clinical trials.
• The companies' products may not be approved by regulatory agencies.
• Their technologies may not be validated as they progress, and their methods may not be accepted by the scientific community.
• Inability to retain or attract key employees whose knowledge is essential to product development.
• Unforeseen scientific difficulties may develop with the products being advanced.
• Products may wind up being more expensive than anticipated.
• Results in the laboratory may not translate to equally good results in real clinical settings.
• Results of preclinical studies may not correlate with the results of human clinical trials.
• The companies' patents may not be sufficient.
• Their products may harm recipients.
• Changes in legislation may adversely impact either or both companies.
• Inability to timely develop and introduce new technologies, products, and applications.
• Loss of market share and pressure on pricing resulting from competition.

Future Outlook

The combined entity, NewcelX, intends to be a Nasdaq-listed clinical-stage biotech with a robust pipeline spanning neurodegenerative disease (AstroRx for ALS in Phase IIa), diabetes (IsletRx), and CNS disorders via the DOXA platform. The company anticipates rapidly initiating a Phase IIa multi-site clinical trial for AstroRx targeting ALS, a Phase I study for IsletRx in Type I diabetes, and continued preclinical progression of AEX-2/AEX-41 toward late-stage development for indications like narcolepsy and neurodegeneration. The merger is expected to close in the near future, followed by an energized integration phase and accelerated clinical momentum, aiming for meaningful value creation and enhanced long-term shareholder value.

Management Comments

• "We are delighted to share a summary of NLS Pharmaceutics achieved milestones since the fourth quarter of 2024." Alexander C. Zwyer, CEO, NLS Pharmaceutics Ltd.
• "These financing events have not only strengthened our balance sheet, but have extended our cash runway, enabling us to pursue continued research & development efforts and proceed with the execution of the merger." Alexander C. Zwyer, CEO, NLS Pharmaceutics Ltd.
• "We are excited about the upcoming merger, which aligns with our strategic goals and will enable us to provide comprehensive therapeutic options for patients." Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem.
• "By joining forces, we can better serve those with diabetes and combat its complexity. This merger demonstrates a commitment to innovation, patient care, and long-term value." Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem.
• "We are committed to ensuring a smooth integration process as we move forward, following the completion of the merger." Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem.
• "With a fortified capital structure, and a unified board guiding our research and development direction, we are strategically positioned for meaningful value creation." Alexander C. Zwyer, CEO, NLS Pharmaceutics Ltd.
• "We anticipate the closing of the merger to occur in the near future, followed by an energized integration phase and accelerated clinical momentum." Alexander C. Zwyer, CEO, NLS Pharmaceutics Ltd.
• "Together, we will accelerate development, diversify our pipeline, and enhance long-term shareholder value." Alexander C. Zwyer, CEO, NLS Pharmaceutics Ltd.

Industry Context

This announcement highlights a strategic consolidation within the biopharmaceutical sector, specifically targeting central nervous system disorders and diabetes. The merger of NLS Pharmaceutics, with its dual orexin receptor agonist platform, and Kadimastem, a cell therapy company focused on neurodegenerative diseases and diabetes, creates a diversified clinical-stage biotech. This move aligns with a broader industry trend of companies seeking to expand their pipelines and therapeutic areas through mergers and acquisitions to achieve greater scale, diversify risk, and leverage complementary technologies, particularly in high-need areas like ALS and Type 1 Diabetes. The combined entity, NewcelX, aims to compete in these specialized therapeutic markets with a strengthened capital structure.

Stakeholder Impact

• Shareholders: Expected to benefit from a fortified capital structure, diversified pipeline, and potential long-term value creation; NLS shareholders will continue to benefit from legacy assets (Mazindol ER) through contingent value rights.
• Patients: The merger aims to provide comprehensive therapeutic options for patients with diabetes and CNS disorders, including ALS, and improve their lives.
• Employees: Implied integration process following the merger, suggesting potential changes or restructuring.

Next Steps

• Final NLS shareholder vote on the merger.
• Completion of the merger with Kadimastem, targeted for early Q3 2025, subject to regulatory requirements.
• Initiation of Phase IIa multi-site clinical trial for AstroRx, targeting ALS.
• Initiation of Phase I study for IsletRx in Type I diabetes.
• Continued preclinical progression of AEX-2/AEX-41 toward late-stage development (e.g., narcolepsy, neurodegeneration).
• Energized integration phase following merger closing.
• Acceleration of clinical momentum.

Key Dates

Keywords

Biopharmaceutical, Clinical-stage, Central Nervous System disorders, CNS, Merger, Acquisition, Kadimastem, NLS Pharmaceutics, NewcelX, AstroRx, ALS, Amyotrophic Lateral Sclerosis, IsletRx, Type 1 Diabetes, DOXA platform, AEX-2, Mazindol ER, Fentanyl-induced reward behaviors, FDA, Pre-IND Meeting, Equity financing, Clinical trials, Neurodegenerative disease, Cell therapy